JP4004088B2 - 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質 - Google Patents

免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質 Download PDF

Info

Publication number
JP4004088B2
JP4004088B2 JP26910596A JP26910596A JP4004088B2 JP 4004088 B2 JP4004088 B2 JP 4004088B2 JP 26910596 A JP26910596 A JP 26910596A JP 26910596 A JP26910596 A JP 26910596A JP 4004088 B2 JP4004088 B2 JP 4004088B2
Authority
JP
Japan
Prior art keywords
protein
cells
ifn
production
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP26910596A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09289896A5 (cg-RX-API-DMAC7.html
JPH09289896A (ja
Inventor
研志 穐田
善之 額田
光清 藤井
忠雄 谷本
雅司 栗本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hayashibara Seibutsu Kagaku Kenkyujo KK
Original Assignee
Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hayashibara Seibutsu Kagaku Kenkyujo KK filed Critical Hayashibara Seibutsu Kagaku Kenkyujo KK
Priority to JP26910596A priority Critical patent/JP4004088B2/ja
Priority to CA002186423A priority patent/CA2186423C/en
Priority to EP96306997A priority patent/EP0767178A1/en
Priority to AU65881/96A priority patent/AU724940B2/en
Priority to NZ299943A priority patent/NZ299943A/en
Priority to US08/832,198 priority patent/US6242255B1/en
Publication of JPH09289896A publication Critical patent/JPH09289896A/ja
Priority to US09/752,510 priority patent/US6441138B2/en
Priority to US09/819,902 priority patent/US6403079B1/en
Publication of JPH09289896A5 publication Critical patent/JPH09289896A5/ja
Priority to KR1020040101627A priority patent/KR100491365B1/ko
Priority to US11/580,922 priority patent/US7355014B2/en
Application granted granted Critical
Publication of JP4004088B2 publication Critical patent/JP4004088B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP26910596A 1994-11-15 1996-09-20 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質 Expired - Fee Related JP4004088B2 (ja)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP26910596A JP4004088B2 (ja) 1995-09-26 1996-09-20 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
CA002186423A CA2186423C (en) 1995-09-26 1996-09-25 Protein which induces interferon-gamma production by immunocompetent cell
EP96306997A EP0767178A1 (en) 1995-09-26 1996-09-26 Protein which induces interferon-gamma production by immunocompetent cell
AU65881/96A AU724940B2 (en) 1995-09-26 1996-09-26 Protein which induces interferon-gamma production by immunocompetent cell
NZ299943A NZ299943A (en) 1996-09-20 1996-12-16 Protein stimulator of ifn-gamma in immunocompetant cells
US08/832,198 US6242255B1 (en) 1995-09-26 1997-04-08 Protein which induces interferon-gamma production by immunocompetent cell
US09/752,510 US6441138B2 (en) 1995-09-26 2001-01-03 Protein which induces interferon-γ production by immunocompetent cell
US09/819,902 US6403079B1 (en) 1995-09-26 2001-03-29 Process for producing a pharmaceutical composition containing a protein which induces interferon-γ production by an immunocompetent cell
KR1020040101627A KR100491365B1 (en) 1995-09-26 2004-12-06 Protein which induces interferon-gamma production by immunocompetent cell
US11/580,922 US7355014B2 (en) 1994-11-15 2006-10-16 Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP27072595 1995-09-26
JP7-270725 1996-02-29
JP6743496 1996-02-29
JP8-67434 1996-02-29
JP26910596A JP4004088B2 (ja) 1995-09-26 1996-09-20 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質

Publications (3)

Publication Number Publication Date
JPH09289896A JPH09289896A (ja) 1997-11-11
JPH09289896A5 JPH09289896A5 (cg-RX-API-DMAC7.html) 2004-09-30
JP4004088B2 true JP4004088B2 (ja) 2007-11-07

Family

ID=27299437

Family Applications (1)

Application Number Title Priority Date Filing Date
JP26910596A Expired - Fee Related JP4004088B2 (ja) 1994-11-15 1996-09-20 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質

Country Status (6)

Country Link
US (3) US6242255B1 (cg-RX-API-DMAC7.html)
EP (1) EP0767178A1 (cg-RX-API-DMAC7.html)
JP (1) JP4004088B2 (cg-RX-API-DMAC7.html)
KR (1) KR100491365B1 (cg-RX-API-DMAC7.html)
AU (1) AU724940B2 (cg-RX-API-DMAC7.html)
CA (1) CA2186423C (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
CA2238885A1 (en) * 1995-12-29 1997-07-10 Incyte Pharmaceuticals, Inc. Nucleic acids encoding interferon gamma inducing factor-2
JP3955352B2 (ja) 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
US6432678B1 (en) * 1999-06-21 2002-08-13 Smithkline Beecham Corporation Macaca cynomolgus IL 18
EP1257585A2 (en) * 2000-02-10 2002-11-20 Basf Aktiengesellschaft Antibodies that bind human interleukin-18 and methods of making and using
US20030044398A1 (en) * 2001-03-20 2003-03-06 Robl James M. Methods for producing antibodies in mammals
MD2053C2 (ro) * 2001-07-10 2003-07-31 Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова Remediu cu acţiune interferonogenă
JP4059648B2 (ja) * 2001-08-28 2008-03-12 独立行政法人科学技術振興機構 経口用サイトカイン誘導剤
TW200510454A (en) 2003-04-15 2005-03-16 Smithkline Beecham Corp Conjugates comprising human IL-18 and substitution mutants thereof
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP2161032B1 (en) 2004-08-20 2011-09-28 GlaxoSmithKline LLC Healing of wounds by administering human IL-18
CA2642706C (en) * 2006-02-17 2017-08-01 Atsuo Sekiyama Biological load indicator and method of measuring biological load
PE20090190A1 (es) 2007-03-23 2009-03-22 Smithkline Beecham Corp Combinacion de anticuerpos anti-cd20 y polipeptidos de il-18
US8168165B2 (en) 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
US11219672B2 (en) 2014-08-07 2022-01-11 Haruki Okamura Therapeutic agent for cancer which comprises combination of IL-18 and molecule-targeting antibody

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2016015B (en) * 1978-01-22 1982-05-06 Hayashibara Co Method of preparing interferon and preparations containing interferon
US5457038A (en) * 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
EP0692536B1 (en) * 1994-07-14 2000-11-22 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo IFN-Y production inducing protein and monoclonal antibody of the same
JP3109018B2 (ja) 1994-07-14 2000-11-13 株式会社林原生物化学研究所 インターフェロン−γの産生を誘導する蛋白質
TW464656B (en) * 1994-11-15 2001-11-21 Hayashibara Biochem Lab Interferon-gamma production inducing polypeptide monoclonal antibody, and agent for interferon-gamma susceptive disease
JP2724987B2 (ja) * 1994-11-15 1998-03-09 株式会社林原生物化学研究所 インターフェロン−γの産生を誘導するポリペプチド
US6060283A (en) * 1996-06-27 2000-05-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding human interleukin-18 (IL-18, interferon-γ inducing factor)
JPH1080270A (ja) * 1996-07-19 1998-03-31 Hayashibara Biochem Lab Inc ポリペプチドをプロセッシングする酵素
US5891662A (en) * 1997-11-13 1999-04-06 Infectech, Inc. Method for determining the antimicrobial agent sensitivity of a nonparaffinophilic hydrophobic microorganism

Also Published As

Publication number Publication date
US6441138B2 (en) 2002-08-27
US20010018212A1 (en) 2001-08-30
AU6588196A (en) 1997-05-15
CA2186423C (en) 2007-06-26
US6242255B1 (en) 2001-06-05
US6403079B1 (en) 2002-06-11
EP0767178A1 (en) 1997-04-09
KR100491365B1 (en) 2005-05-24
AU724940B2 (en) 2000-10-05
JPH09289896A (ja) 1997-11-11
CA2186423A1 (en) 1997-03-27

Similar Documents

Publication Publication Date Title
JP4004088B2 (ja) 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
JP2002515247A (ja) Ｉｌ−２の選択的アゴニスト及びアンタゴニスト
JP4024366B2 (ja) ポリペプチド
JPH029394A (ja) ヒトインターフエロンベーター２、その精製法及びその用途
JP4832640B2 (ja) Ｈｓｐ７０タンパク質の新規使用
KR20010074925A (ko) 인터류킨-18 결합 단백질
AU707019B2 (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
US6207641B1 (en) Pharmaceutical composition containing IFN-γ inducing polypeptide or factor for treating and/or preventing IFN-γ susceptive diseases
NO173144B (no) Fremgangsmaate til fremstilling av interferongamma
US5871725A (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
JPH0296598A (ja) リンフォカイン活性化キラー細胞誘導抑制因子ｌａｋｓｆ，その製造法およびそれを有効成分とする免疫抑制剤
US7135458B1 (en) Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
KR100491366B1 (ko) 면역담당세포에의한인터페론-γ의생산을유도하는단백질
JP3993652B2 (ja) 感受性疾患剤
JP4216950B2 (ja) インターロイキン−１８結合蛋白質
JP4026923B2 (ja) ポリペプチド
JPH02308799A (ja) 癌転移抑制因子の製造方法
JP2589094B2 (ja) 抗悪性腫瘍剤
NZ299943A (en) Protein stimulator of ifn-gamma in immunocompetant cells
EP1033997B1 (en) Method of mobilizing hematopoietic stem cells
JP2846331B2 (ja) 骨髄細胞分化増殖因子、その産生細胞及びその製法
JP4462706B2 (ja) マクロファージ遊走阻止因子を含有する造血幹細胞増殖剤
CN107098978A (zh) 一种抗肿瘤和免疫增强双重功效融合蛋白
CN119490578A (zh) 一种il-2突变体及其应用
JPH08333274A (ja) 悪性腫瘍治療用キット

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20060207

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20070123

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20070814

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20070821

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100831

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110831

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120831

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120831

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130831

Year of fee payment: 6

LAPS Cancellation because of no payment of annual fees